Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
173 hedge funds and large institutions have $1.03B invested in Achillion Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 77 increasing their positions, 40 reducing their positions, and 38 closing their positions.
152% more call options, than puts
Call options by funds: $46.4M | Put options by funds: $18.4M
93% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 40
4% less capital invested
Capital invested by funds: $1.08B → $1.03B (-$40.7M)
3% less funds holding
Funds holding: 179 → 173 (-6)
13% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 38
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$98M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$43.2M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$31.3M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$19.1M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$35.9M |
| 2 |
Goldman Sachs
New York
|
-$26.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$17.3M |
| 5 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$13.8M |
ACHN Hedge Fund Activity: Q1 2015 in Review
173 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2015, worth a combined $1.03B — down 3.8% from $1.08B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of ACHN and 33 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 77 added.
The largest buyer was Wellington Management Group, adding an estimated $98M. The largest seller was Bain Capital Public Equity Management, exiting entirely with an estimated $35.9M sold.
- 173 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2015, down from 179 in Q4 2014.
- Funds reported $1.03B of Achillion Pharmaceuticals stock for Q1 2015, down 3.8% quarter-over-quarter.
- 33 funds opened new Achillion Pharmaceuticals positions in Q1 2015 and 38 closed out, a net change of -5 holders.
- The largest Achillion Pharmaceuticals buyer in Q1 2015 was Wellington Management Group, an estimated $98M added.
- The largest Achillion Pharmaceuticals seller in Q1 2015 was Bain Capital Public Equity Management, an estimated $35.9M sold.
Based on aggregated 13F filings for Q1 2015.